#102

ApoE genes and increases in lipids from rapamycin:

This study shows that the apo E polymorphism is a factor that could influence the development of hyperlipidemia in transplant recipients undergoing sirolimus treatment. We found a higher frequency of the allele E4 in patients with hyperlipidemia and sirolimus treatment, as well as a lower frequency of the allele E3 when compared with the patients with normal lipid profile and sirolimus treatment. In addition, we showed an association between higher triglycerides and cholesterol levels and the alleles E2 and E4 in the patients with hyperlipidemia and sirolimus treatment. It is possible that the interaction of genetic influences (apo E polymorphism) and environmental factors (immunosuppressive therapy with sirolimus) could affect the plasma lipid levels causing a more important increase of TG levels and CT levels in subjects with the apo E2 and apo E4 alleles than in carriers of the apo E3 allele.

Apolipoprotein E Genotypes as Predictors of High-Risk Groups for Developing Hyperlipidemia in Kidney Transplant Recipients Undergoing Sirolimus Treatment 2005

1 Like